文献速递银屑病与炎症性皮肤病

ErbB3结合蛋白1的Khib修饰下调通过TIF-IA介导的rRNA合成促进角质形成细胞增殖

Downregulation of lysine 2-hydroxyisobutyrylation of ErbB3 binding protein 1 at amino acid 210 promotes keratinocyte proliferation via induction of transcription initiation factor IA-mediated rRNA synthesis.
PubMed 文献 · Br J Dermatol · 2024-01-01

该研究通过液相色谱-串联质谱分析银屑病皮损与健康对照表皮中Khib修饰蛋白,发现银屑病皮损中EBP1第210位赖氨酸Khib修饰(EBP1Khib210)下调。体外实验表明EBP1Khib210下调增强角质形成细胞活力、增殖和存活并抑制凋亡;Pa2g4K210A小鼠表现出更严重的银屑病样皮损和角质形成细胞增殖增强。机制上EBP1K210A突变增加EBP1与核内Akt相互作用,抑制MDM2介导的TIF-IA泛素化,导致rRNA合成增加和角质形成细胞增殖。

要点

  • 银屑病皮损中EBP1Khib210表达下调,有效治疗后上调。
  • EBP1Khib210下调通过Akt-TIF-IA-rRNA轴促进角质形成细胞增殖。
  • Khib修饰可能成为银屑病潜在治疗靶点。

核心结论

  • EBP1Khib210下调通过调控Akt信号和TIF-IA介导的rRNA合成促进角质形成细胞增殖,参与银屑病发病。

研究设计与样本

  • 采用液相色谱-串联质谱分析银屑病皮损与健康对照表皮中Khib修饰蛋白。
  • 构建EBP1Khib210下调的突变细胞和Pa2g4K210A小鼠以研究功能效应。

主要发现

  • 银屑病皮损中Khib修饰谱与对照不同,EBP1Khib210在银屑病皮损和咪喹莫特诱导的小鼠银屑病中下调。
  • 有效治疗后银屑病患者EBP1Khib210表达上调。
  • 体外实验显示EBP1Khib210下调增强角质形成细胞活力、增殖和存活,抑制凋亡。
  • Pa2g4K210A小鼠表现出更严重的银屑病样皮损和角质形成细胞增殖增强。
  • EBP1K210A突变增加EBP1与核内Akt相互作用,抑制MDM2介导的TIF-IA泛素化,增加rRNA合成。

临床怎么用

  • 调控EBP1Khib210或Khib修饰可能为银屑病治疗提供新策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Psoriasis is a prevalent chronic inflammatory dermatosis characterized by the excessive proliferation of keratinocytes (KCs). Lysine 2-hydroxyisobutyrylation (Khib) is a newly identified post-translational modification that regulates various biological processes. Abnormal Khib modification has been associated with the development of autoimmune diseases. OBJECTIVES: To investigate the abnormal Khib modification profile and its pathogenic role in psoriasis. METHODS: Liquid chromatography-tandem mass spectrometry was used to analyse Khib-modified proteins in the epidermis of psoriasis lesions and healthy control skin. Mutated cells and mice with downregulated Khib modification of ErbB3 binding protein 1 (EBP1) at amino acid 210 (EBP1Khib210) were generated, to investigate the functional effects of EBP1Khib210 in psoriasis. RESULTS: Omics analysis revealed dysregulation of Khib modification in psoriatic lesions, exhibiting a distinct profile compared with controls. We found downregulation of EBP1Khib210 in psoriatic lesions and mice with imiquimod-induced psoriasis. Notably, expression of EBP1Khib210 was upregulated in patients with psoriasis following effective treatment. Decreased EBP1Khib210 enhanced KC viability, proliferation and survival but inhibited apoptosis in vitro. Additionally, Pa2g4K210A mice with downregulated Ebp1Khib210 exhibited more severe psoriatic lesions and enhanced KC proliferation. Moreover, we found that the EBP1K210A mutation increased the interaction between EBP1 and nuclear protein kinase B (Akt), thereby inhibiting mouse double minute 2-mediated transcription initiation factor IA (TIF-IA) ubiquitination and resulting in increased rRNA synthesis and KC proliferation. Downregulation of EBP1Khib210 was attributed to an inflammation-induced increase in histone deacetylase 2 expression. CONCLUSIONS: Downregulation of EBP1Khib210 promoted KC proliferation by modulating Akt signalling and TIF-IA-mediated rRNA synthesis. These insights into Khib modification provide better understanding of the pathogenesis of psoriasis and suggest potential therapeutic targets. Psoriasis is a common skin disease that affects around 2% to 3% of the population. A type of skin cell called ‘keratinocytes’ proliferate in psoriasis. As well as this, chemical changes called ‘post-translational modifications’ can take place in proteins after they are produced in cells. For example, one type of modification is ‘lysine 2-hydroxyisobutyrylation’ or ‘Khib’ for short. Research on Khib in psoriasis is rare, and it is important to understand more about it and its effects on keratinocytes. In this study, we looked at Khib modification and its role in psoriasis. We found that the amount of Khib modification was different in skin affected by psoriasis, in unaffected skin from people with psoriasis and in skin from healthy people. We also found that the Khib modification of a protein called ‘EBP1’ was reduced in people with psoriasis. We found that the inflammation found in psoriasis decreased the amount of Khib modification of EBP1 at a particular position (amino acid 210), which affected certain interactions. The abnormalities caused an increase in the number of keratinocytes, which is a feature of psoriasis. This suggests that Khib modification of EPB1 at a particular position could contribute to the development of psoriasis. The findings from this study increase our knowledge of Khib modification in regulating keratinocytes. Manipulation of Khib modification could provide a new approach for the treatment of psoriasis.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Li J, Wang Y, Niu X, et al. Downregulation of lysine 2-hydroxyisobutyrylation of ErbB3 binding protein 1 at amino acid 210 promotes keratinocyte proliferation via induction of transcription initiation factor IA-mediated rRNA synthesis. Br J Dermatol. 2024. PMID: 38752336. doi:10.1093/bjd/ljae194

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。